bluebird bio Inc (BLUE)

74.80
2.60 3.70
NASDAQ : Health Care
Prev Close 72.15
Open 72.00
Day Low/High 71.31 / 72.80
52 Wk Low/High 35.37 / 169.16
Volume 117.13K
Avg Volume 1.54M
Exchange NASDAQ
Shares Outstanding 37.30M
Market Cap 2.60B
EPS -4.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Bluebird Bio Presents New Data From HGB-205 Study Of LentiGlobinTM Drug Product In Patients With Transfusion-Dependent ß-Thalassemia (TDT) And Severe Sickle Cell Disease At American Society Of Hematology (ASH) Annual Meeting

Bluebird Bio Presents New Data From HGB-205 Study Of LentiGlobinTM Drug Product In Patients With Transfusion-Dependent ß-Thalassemia (TDT) And Severe Sickle Cell Disease At American Society Of Hematology (ASH) Annual Meeting

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced the...

Bluebird Bio Announces Management Appointments

Bluebird Bio Announces Management Appointments

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced two new...

Jim Cramer's 'Mad Money' Recap: This Rotation's Too Hard for the Bulls

Jim Cramer's 'Mad Money' Recap: This Rotation's Too Hard for the Bulls

Cramer wonders if this market has gotten too enthusiastic for the Trump agenda.

Oil Prices Keep Rising on OPEC Deal; Bluebird, Celgene T-Cell Therapy Sees Success

Oil Prices Keep Rising on OPEC Deal; Bluebird, Celgene T-Cell Therapy Sees Success

Oil prices continued their upward climb Thursday, buoyed by Wednesday's landmark OPEC agreement.

Bluebird Bio Announces Interim Phase 1 Dose Escalation Data For Its Anti-BCMA CAR T Product Candidate In Patients With Relapsed/Refractory Multiple Myeloma

Bluebird Bio Announces Interim Phase 1 Dose Escalation Data For Its Anti-BCMA CAR T Product Candidate In Patients With Relapsed/Refractory Multiple Myeloma

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced that interim...

Bluebird, Celgene T-Cell Therapy Eliminates Multiple Myeloma With Minimal Side Effects

Bluebird, Celgene T-Cell Therapy Eliminates Multiple Myeloma With Minimal Side Effects

'We're seeing impressive, early responses with BB2121 without the toxicity,' says Bluebird CEO Nick Leschly.

How Buying Blue Apron Ahead of any IPO Could Leave You Blue

How Buying Blue Apron Ahead of any IPO Could Leave You Blue

Remembering old ticker missteps ahead of any IPOs by unicorns.

Bluebird Bio To Present New Data From Novel Anti-BCMA CAR T Cell Therapy Bb2121 At EORTC-NCI-AACR Molecular Targets And Cancer Therapies Symposium

Bluebird Bio To Present New Data From Novel Anti-BCMA CAR T Cell Therapy Bb2121 At EORTC-NCI-AACR Molecular Targets And Cancer Therapies Symposium

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced that interim...

The Great 'ASH16' Abstract Drop Mostly Causes Drug Stocks to Do Same

The Great 'ASH16' Abstract Drop Mostly Causes Drug Stocks to Do Same

The American Society of Hematology (ASH) annual meeting is one of the most important medical conferences held each year, focusing on new drugs to treat blood-related diseases, including blood cancers.

Bluebird Bio To Present New Data From Three LentiGlobinTM Clinical Studies At American Society Of Hematology (ASH) Annual Meeting

Bluebird Bio To Present New Data From Three LentiGlobinTM Clinical Studies At American Society Of Hematology (ASH) Annual Meeting

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced that data...

Bluebird Bio Reports Third Quarter 2016 Financial Results And Recent Operational Progress

Bluebird Bio Reports Third Quarter 2016 Financial Results And Recent Operational Progress

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today reported business...

Bluebird Bio To Present At Two Investor Conferences In November

Bluebird Bio To Present At Two Investor Conferences In November

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that...

Why Celgene Is a Core Biotech Holding

Why Celgene Is a Core Biotech Holding

Celgene's days of stellar growth will continue to stretch far into the future.

Trader's Daily Notebook: You Might Consider Selling Facebook

Trader's Daily Notebook: You Might Consider Selling Facebook

Do that if you like top ticking crowd favorites, but set a protective stop.

Bluebird Bio Shares End Friday's Session Down 13%

Bluebird Bio Shares End Friday's Session Down 13%

The biotech firm's stock sold off sharply during Friday's trading session -- one day after announcing improvements to its gene therapy for rare blood diseases.

Bluebird Bio Provides Update On LentiGlobin™ Programs And Research And Development Strategy At Gene Therapy Day

Bluebird Bio Provides Update On LentiGlobin™ Programs And Research And Development Strategy At Gene Therapy Day

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, will outline today key...

Bluebird Bio Announces Topics For Gene Therapy Day, October Investor Presentation

Bluebird Bio Announces Topics For Gene Therapy Day, October Investor Presentation

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced the...

Buy These 4 Stocks and Beat Biotech's Slump

Buy These 4 Stocks and Beat Biotech's Slump

Brad Loncar, CEO of Loncar Investment said don't throw in the towel on biotech stocks yet.

Bluebird Bio And Medigene Establish Strategic T Cell Receptor (TCR) Alliance In Cancer Immunotherapy

Bluebird Bio And Medigene Establish Strategic T Cell Receptor (TCR) Alliance In Cancer Immunotherapy

Medigene AG (MDG1, Frankfurt, Prime Standard), Germany, and bluebird bio, Inc.

Four Stellar Stocks to Beat the Biotech Slump

Four Stellar Stocks to Beat the Biotech Slump

Biotech stocks are struggling this year, but investors should not throw in the towel on Amgen, Gilead, bluebird and Bellicum

OPEC, HP, Ulta Salon and Lululemon: Jim Cramer's Views

OPEC, HP, Ulta Salon and Lululemon: Jim Cramer's Views

Jim Cramer shares his views on OPEC, luxury brands and tech.

'Mad Money' Lightning Round: Buy, Buy, Buy Advanced Micro Devices

'Mad Money' Lightning Round: Buy, Buy, Buy Advanced Micro Devices

Cramer says Bluebird Bio is too speculative for him but he likes Enterprise Products Partners.

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

The market is fearful. Use that fear to buy, Cramer says.

LentiGlobin™ Investigational Gene Therapy For Transfusion-Dependent Beta-Thalassemia Accepted Into European Medicines Agency's PRIME Program

LentiGlobin™ Investigational Gene Therapy For Transfusion-Dependent Beta-Thalassemia Accepted Into European Medicines Agency's PRIME Program

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that...

Bluebird Bio (BLUE) Stock Jumping, Goldman Adds to Conviction Buy List

Bluebird Bio (BLUE) Stock Jumping, Goldman Adds to Conviction Buy List

Bluebird Bio (BLUE) stock was raised to 'conviction buy' at Goldman on Thursday.

Here's a Reason Why Bluebird Bio (BLUE) Stock Is Jumping Today

Here's a Reason Why Bluebird Bio (BLUE) Stock Is Jumping Today

Bluebird Bio (BLUE) could be a takeover target for Takeda Pharmaceutical (TKPYY), Citi said on Wednesday.

Bluebird Bio Announces Webcast Of Gene Therapy Day

Bluebird Bio Announces Webcast Of Gene Therapy Day

bluebird bio, Inc. ( Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that it...

Bluebird Improves Its Gene Therapy, Removing an Investor Concern

Bluebird Improves Its Gene Therapy, Removing an Investor Concern

Bluebird Bio removed a significant concern investors had about its gene therapy manufacturing process, sending shares higher Thursday.